Literature DB >> 30850032

Cinchona Alkaloids-Derivatives and Applications.

Przemysław J Boratyński1, Mariola Zielińska-Błajet1, Jacek Skarżewski2.   

Abstract

Major Cinchona alkaloids quinine, quinidine, cinchonine, and cinchonidine are available chiral natural compounds (chiral pool). Unlike many other natural products, these alkaloids are available in multiple diastereomeric forms which are separated on an industrial scale. The introduction discusses in short conformational equilibria, traditional separation scheme, biosynthesis, and de novo chemical syntheses. The second section concerns useful chemical applications of the alkaloids as chiral recognition agents and effective chiral catalysts. Besides the Sharpless ethers and quaternary ammonium salts (chiral PTC), the most successful bifunctional organocatalysts are based on 9-amino derivatives: thioureas and squaramides. The third section reports the main transformations of Cinchona alkaloids. This covers reactions of the 9-hydroxyl group with the retention or inversion of configuration. Specific Cinchona rearrangements enlarging [2.2.2]bicycle of quinuclidine to [3.2.2] products are connected to the 9-OH substitution. The syntheses of numerous esterification and etherification products are described, including many examples of bi-Cinchona alkaloid ethers. Further derivatives comprise 9-N-substituted compounds. The amino group is introduced via an azido function with the inversion of configuration at the stereogenic center C9. The 9-epi-amino-alkaloids provide imines, amides, imides, thioureas, and squaramides. The syntheses of 9-carbon-, 9-sulfur-, and 9-selenium-substituted derivatives are discussed. Oxidation of the hydroxyl group of any alkaloid gives ketones, which can be selectively reduced, reacted with Grignard reagents, or subjected to the Corey-Chaykovsky reaction. The alkaloids were also partially degraded by splitting C4'-C9 or N1-C8 bonds. In order to immobilize Cinchona alkaloids the transformations of the 3-vinyl group were often exploited. Finally, miscellaneous functionalizations of quinuclidine, quinoline, and examples of various metal complexes of the alkaloids are considered.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Asymmetric synthesis; Chiral ligands; Chiral recognition; Cinchonidine; Cinchonine; Organocatalysis; Quinidine; Quinine

Mesh:

Substances:

Year:  2019        PMID: 30850032     DOI: 10.1016/bs.alkal.2018.11.001

Source DB:  PubMed          Journal:  Alkaloids Chem Biol        ISSN: 1099-4831


  6 in total

1.  Re-engineering natural products to engage new biological targets.

Authors:  Stephen E Motika; Paul J Hergenrother
Journal:  Nat Prod Rep       Date:  2020-11-18       Impact factor: 13.423

Review 2.  A Review of Modifications of Quinoline Antimalarials: Mefloquine and (hydroxy)Chloroquine.

Authors:  Dawid J Kucharski; Michalina K Jaszczak; Przemysław J Boratyński
Journal:  Molecules       Date:  2022-02-02       Impact factor: 4.411

3.  Aminations and arylations by direct C-O activation for the design of 7,8-dihydro-6H-5,8-ethanopyrido[3,2-d]pyrimidines.

Authors:  Mazarine Laurent; Stéphane Bostyn; Mathieu Marchivie; Yves Robin; Sylvain Routier; Frédéric Buron
Journal:  RSC Adv       Date:  2021-05-28       Impact factor: 4.036

4.  Stereoselective Domino Rearrangement peri-Annulation of Cinchona Alkaloid Derivatives with 8-Bromo-1-naphthyl Grignard.

Authors:  Przemysław J Boratyński
Journal:  J Org Chem       Date:  2022-08-23       Impact factor: 4.198

Review 5.  The Potential of Traditional Knowledge to Develop Effective Medicines for the Treatment of Leishmaniasis.

Authors:  Luiz Felipe D Passero; Erika Dos Santos Brunelli; Thamara Sauini; Thais Fernanda Amorim Pavani; Jéssica Adriana Jesus; Eliana Rodrigues
Journal:  Front Pharmacol       Date:  2021-06-08       Impact factor: 5.810

6.  Enantioselective total synthesis of the unnatural enantiomer of quinine.

Authors:  Shinya Shiomi; Remi Misaka; Mayu Kaneko; Hayato Ishikawa
Journal:  Chem Sci       Date:  2019-09-27       Impact factor: 9.825

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.